NEW YORK, June 04, 2024 (GLOBE NEWSWIRE) -- Cellectis (the "Company") (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, announced today that the European Commission (EC) has granted an Orphan Drug Designation (ODD) to its product candidate UCART22, for the treatment of Acute Lymphoblastic Leukemia (ALL). UCART22 is an allogeneic CAR T-cell product candidate targeting CD22 and evaluated in ...

Cellectis S.A. (NASDAQ:CLLS) Q1 2024 Earnings Conference Call May 29, 2024 8:00 AM ET Company Participants Arthur Stril - Interim-CFO André Choulika - CEO Mark Frattini - Chief Medical Officer Conference Call Participants Gena Wang - Barclays Dev Prasad - Jefferies Salveen Richter - Goldman Sachs Jack Allen - Baird Luisa Morgado - Van Lanschot Kempen Kuan-Hung Lin - Wells Fargo Operator Good morning, everyone, and welcome to the Cellectis First Quarter 2024 Earnings Call. [Operator Instructions] Please be a ...

NEW YORK, May 29, 2024 (GLOBE NEWSWIRE) -- Cellectis (the "Company") (NASDAQ:CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, announced today that it will hold its annual general meeting on June 28, 2024 at 2:30 p.m. CET at the Biopark auditorium, 11 rue Watt, 4th floor, 75013 Paris, France. About Cellectis Cellectis is a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life- sav ...

Investor Relations contacts: Arthur Stril, Interim Chief Financial Officer, +1 (347) 809 5980, investors@cellectis.com Ashley R. Robinson, LifeSci Advisors, +1 617 430 7577 Attachment Cellectis is a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life- saving cell and gene therapies. Cellectis utilizes an allogeneic approach for CAR-T immunotherapies in oncology, pioneering the concept of off-the-shelf and ready-to-use gene-edited CAR T-cells to treat cancer patien ...

• Cellectis announced completion of the additional equity investment of $140M by AstraZeneca • Cash position of $143 million as of March 31, 20241; cash runway projection into 20262 • Conference call and webcast scheduled for tomorrow, May 29, 2024 at 8:00AM ET / 2:00PM CET NEW YORK, May 28, 2024 (GLOBE NEWSWIRE) -- Cellectis (the "Company") (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene editing platform to develop life-saving cell and gene therapie ...

as Exhibit 99.1 | --- | --- | --- | |--------------|---------------------------------------------------------------------------------------------------------|-------| | PART I – | FINANCIAL INFORMATION | 3 | | Item 1. | Interim Condensed Consolidated Financial Statements (Unaudited) | 3 | | Item 2. | Management's Discussion & Analysis of Financial Condition and Results of Operations | 42 | | Item 3. | Quantitative and Qualitative Disclosures About Market Risks | 52 | | Item 4. | Controls and Procedures | 52 ...

NEW YORK, May 27, 2024 (GLOBE NEWSWIRE) -- Cellectis (the "Company") (Euronext Growth: ALCLS- NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, today announced that it will report financial results for the first quarter 2024 ending March 31, 2024 on Tuesday, May 28, 2024 after the close of the US market. The publication will be followed by an investor conference call and webcast on Wednesday, May 29, 2024 at 8:00 ...

NEW YORK, May 27, 2024 (GLOBE NEWSWIRE) -- Cellectis (the "Company") (Euronext Growth: ALCLS- NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, today announced that it will report financial results for the first quarter 2024 ending March 31, 2024 on Tuesday, May 28, 2024 after the close of the US market. The publication will be followed by an investor conference call and webcast on Wednesday, May 29, 2024 at 8:00 ...

NEW YORK, May 02, 2024 (GLOBE NEWSWIRE) -- Cellectis (the "Company") (NASDAQ:CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, announced today the resignation of Mr. Bing Wang from his position of the Company with immediate effect, and the concomitant appointment of Mr. Arthur Stril as interim Chief Financial Officer, replacing Mr. Bing Wang. Mr. Stril joined Cellectis in 2018 as Vice President, Corporate Development, and ...

Title of each class American Depositary Shares, each representing one American Depositary Shares, each representing one Ordinary shares, nominal value €0.05 per share* Nasdaq Global Market* * Not for trading, but only in connection with the registration of the American Depositary Shares. Securities registered pursuant to Section 12(g) of the Act. None 40 125 Washington, D.C. 20549 FORM 20-F France (Jurisdiction of incorporation or organization) Cellectis S.A. 8, rue de la Croix Jarry 75013 Paris, France (Ad ...